Sound Bioventures – Venture Capital Fund

Sound Bioventures is a venture capital fund investing in about-to-be clinical or clinical stage private companies in Europe and USA developing therapies in specialty therapeutics areas.

We lead, co-lead or follow

Team

As co-investors, you will find us straight forward, transparent, long term oriented and asking “is this the right thing to do for the company” at every step of our decision making.

Read more about the Team

Strategy & Approach

Sound Bioventures is a venture capital fund investing in about-to-be clinical or clinical stage private companies in Europe and USA developing therapies in specialty therapeutics areas.

Read more about Strategy & Approach

Introducing the team

Ester Sklarsky M. Sc., Associate - Sound Bioventures

Ester Sklarsky

M. Sc., Associate

Thomas Tan Ph.D., Principal - Sound Bioventures

Thomas Tan

D. Phil., Principal

Casper Breum M.Sc. and MBA, Managing Partner - Sound Bioventures

Casper Breum

M.Sc. and MBA, Managing Partner

Johan Kördel Ph.D., Managing Partner - Sound Bioventures

Johan Kördel

Ph.D., Managing Partner

Bibhash Mukhopadhyay Ph.D., Managing Partner - Sound Bioventures

Bibhash Mukhopadhyay

Ph.D., Managing Partner

Philip BraininAnalyst, MD, PhD, MBA. Sound Bioventures.

Philip Brainin

Analyst, MD, PhD, MBA

Why the name Sound Bioventures?

Our investment firm started as a Danish-Swedish project with our Danish founder Casper Breum and our Swedish founder Johan Kördel living on either side of the stretch of water between Denmark and Sweden connecting the North and Baltic seas, called “the Sound”. The name is derived from the Scandinavian Öresund (SE) or Øresund (DK). The Sound has always been one of the world’s busiest shipping lanes with approximately 40.000 ships passing through annually. The SE/DK Sound or Greater Copenhagen region is referred to as Medicon Valley and is, like the shipping lane, arguably the busiest in Scandinavia. When our American founder Bibhash Mukhopadhyay joined, our proposition to our investors and portfolio companies took on an expanded global perspective and footprint, spanning an even bigger water passage, the Atlantic Ocean.-“a super sized version of the Sound”! Sound does of course also stand for financially robust investments as well as investments that lead to a healthy body and mind.
Read more about Sound Bioventures »

VarmX raises €30 million Series B2 financing for IND approvaland preparations for pivotal trial

Leiden, The Netherlands, 25 May 2023 – VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces it has successfully raised an additional €30 million in a Series B2 financing round. The round was led by Sound Bioventures whilst the European Innovation Council (EIC) Fund …

Combining instinct & freedom to support startups

Casper Breum says he can usually tell early on if a startup will be a good fit for investment. As a founding partner at Sound Bioventures, Breum is involved in reviewing the roughly six hundred investor pitches from biotech companies the firm evaluates each year. His predictive ability was honed throughout his career, which he […]

We are excited to welcome Arthex to our portfolio

ARTHEx Biotech Announces Closing of €42 M Series B Financing to Advance ATX-01, its Novel Treatment for Myotonic Dystrophy Type 1 (DM1) The ArthemiRTM trial, a Phase I-IIa study of ATX-01 in DM1, is expected to initiate in 2H2023 Round led by Columbus Venture Partners, with participation of European Innovation Council (EIC), Hadean Ventures, Sound …

Breye Therapeutics Strengthens Management Team and Board

“We are thrilled to welcome Peter as CSO. His extensive experience in ophthalmology drug development will be invaluable as we advance our lead compound through clinical development. Gabriela’s appointment to the Board brings significant industry and development experience which will be instrumental as we build a pipeline of novel oral therapies for …